- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, Sutent (sunitinib) / Pfizer
Review, Journal: Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection. (Pubmed Central) - Jan 23, 2024 Although heterogeneity in liposarcoma genetics and phenotype as well as the associated development of resistance to therapy make difficult the introduction of novel therapeutic targets into the clinic, recently a number of targeted therapy drugs were proposed for LPS treatment. The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib.
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2618 / Sino Biopharm
Enrollment open, Trial initiation date, Monotherapy, Metastases: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection (clinicaltrials.gov) - Jan 23, 2024 P1, N=75, Recruiting, The most promising results were shown for CDK4/6 and MDM2 inhibitors as well as for the multi-kinase inhibitors anlotinib and sunitinib. Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
- |||||||||| Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer. (Pubmed Central) - Jan 15, 2024 In patients with advanced BTC, the combination of anlotinib and toripalimab demonstrated remarkable anti-tumor potential, with increased objective response rates (ORR), longer overall survival (OS) and progression-free survival (PFS). Moreover, STK11 and CD8/Foxp3 may be as biomarkers that can predict the
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: In Situ Nanofiber Patch Boosts Postoperative Hepatocellular Carcinoma Immune Activation by Trimodal Combination Therapy. (Pubmed Central) - Jan 11, 2024 Herein, a portable nanofiber patch composing germanium phosphorus (GeP) and anlotinib (AL) was designed to form a versatile platform for molecularly targeted photothermal-immune checkpoint blockade (ICB) trimodal combination therapy...Further validation of the genome sequencing results revealed cell pathways related primarily to regulatory immune effects. This study demonstrates the use of an effective and practical nanofiber patch to improve multimodal therapy of postoperative HCC, with high clinical translation value.
- |||||||||| Tevimbra (tislelizumab) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature. (Pubmed Central) - Jan 9, 2024 In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: Reduction of acute radiation-induced brain injury in rats by anlotinib. (Pubmed Central) - Jan 8, 2024 Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer. This study found that anlotinib has a protective effect against RBI in rats and anlotinib may be a new candidate for the treatment of RBI.
- |||||||||| Benlysta (belimumab) / GSK, Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study (clinicaltrials.gov) - Jan 2, 2024 P=N/A, N=30, Recruiting,
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Aurora-A inhibitor synergistically enhances the inhibitory effect of anlotinib on hepatocellular carcinoma. (Pubmed Central) - Jan 2, 2024 Penpulimab combined with anlotinib demonstrated promising efficacy and manageable safety in R/M HNSCC patients after failure of platinum-based chemotherapy. In summary, we have demonstrated the effectiveness of combining anlotinib with an Aurora-A inhibitor, which expands the potential applications of anlotinib in the clinical treatment of HCC in the future.
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Phase classification, Trial completion date: Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC (clinicaltrials.gov) - Jan 2, 2024 P2, N=45, Active, not recruiting, In summary, we have demonstrated the effectiveness of combining anlotinib with an Aurora-A inhibitor, which expands the potential applications of anlotinib in the clinical treatment of HCC in the future. Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Dec 2023 --> Dec 2026
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date, Metastases: DRAGON - IV: Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer (clinicaltrials.gov) - Dec 31, 2023 P2/3, N=580, Active, not recruiting,
- |||||||||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: ALTER-GO-020: A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer (clinicaltrials.gov) - Dec 27, 2023 P2, N=86, Recruiting, Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P2 | Trial completion date: Dec 2023 --> Dec 2026 Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker: Multi-targeted tyrosine kinase inhibitor reverses resistance to immunotherapy in hepatic sarcomatoid carcinoma. (Pubmed Central) - Dec 18, 2023 Cadonilimab 10?mg/kg Q3W plus anlotinib showed manageable safety and promising efficacy as a first-line chemo-free treatment for advanced NSCLC. Following this regimen, a synergistic treatment approach comprising both anlotinib and sintilimab was instituted, culminating in an ensuing 11
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data, Retrospective data, Journal: Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study. (Pubmed Central) - Dec 13, 2023 The most common grade 3 or higher AEs were increased lipase (19.0%), hypertension (14.3%), and hyponatremia (14.3%) in the anlotinib group. Anlotinib proved to have potential CNS activity and a manageable toxicity profile in patients with SCLC and BM, significantly delaying CNS progression.
- |||||||||| Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial completion date, Metastases: Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) (clinicaltrials.gov) - Dec 11, 2023 P2, N=40, Active, not recruiting, However, further validation is urgently needed through randomized controlled trials with large sample sizes. Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Oct 2026
|